Citius Oncology, Inc.
NASDAQ:CTORDrug Manufacturers - General
+$0.03 today
- Market cap
- $51.83M
- Beta
- 3.42
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$0.42
Volume 0.15M
Average 0.12M
CTOR Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Citius Oncology, Inc.NASDAQ: CTOR
Total Equity · Q2 FY2026 · quarter ended Mar 2026
Total equity broadly unchanged from a year ago
Total equity stood at $35.27M at the end of Q2 FY2026, down 1.0% from a year earlier and down 39.6% from the prior quarter. Over 3 fiscal years it compounded at +7.3% a year.
Context
- Total equity amounted to 35.0% of total assets at the end of Q2 FY2026, down 4.0 pp from a year earlier.
- Total equity increased in 1 of the last 3 fiscal years.
What to watch
Whether total equity keeps falling in the next quarterly balance sheet after a -1.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 44.87M USD
- Year-over-year change
- -2.8%
- 3-year CAGR
- +7.3%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 44.87M | -2.8% |
| FY2024 | 2024-09-30 | 46.14M | +80.7% |
| FY2023 | 2023-09-30 | 25.54M | -29.6% |
| FY2022 | 2022-09-30 | 36.27M | — |
Total Equity vs competitors
How CTOR compares with its peers on the latest reported figures
- CTOR's Mar 2026 total equity of $35.27M is the 5th highest of the 10 companies compared; the peer median is $26.5M.
- Its year-over-year change of -1.0% is the 6th highest of 10, against a peer median of +9.6%.
- Total equity amounts to 35.0% of total assets for CTOR, versus a peer median of 42.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $179.71M | -37.7% | -24.6% | 63.1% | |
| Mar 2026 | $52.93M | +56.5% | -8.1% | 89.7% | |
| Mar 2026 | $42.1M | +9.6% | +16.3% | 62.6% | |
| Mar 2026 | $35.85M | +398.7% | — | 41.3% | |
CTORCitius Oncology, Inc. | Mar 2026 | $35.27M | -1.0% | +7.3% | 35.0% |
| Mar 2026 | $26.5M | -47.5% | +60.1% | 22.5% | |
| Mar 2026 | $24.57M | +211.0% | — | 37.1% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $3.78M | +174.4% | -18.9% | 42.5% |
| Mar 2026 | -$150.42M | -327.7% | — | 29.7% | |
| Mar 2026 | -$254.07M | -20.1% | — | 86.5% | |
| Peer median (excluding CTOR) | $26.5M | +9.6% | -8.1% | 42.5% | |
Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Citius Oncology, Inc.
NASDAQ:CTOR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.